Skip to main content

Advertisement

SpringerLink
Log in

Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients

  • Research Article
  • Published:
Tumor Biology

Abstract

The synuclein gamma (SNCG) protein, a member of neuronal protein family synuclein, has been considered as a promising potential biomarker as an indicator of cancer stage and survival in patients with cancer. The present study was conducted to evaluate the prognostic value of SNCG in patients with esophageal carcinoma (EC). SNCG levels were assessed immunohistochemically in cancer tissues from 73 EC patients. Median age was 57 (range, 29–78) years old. Forty-seven percent of the patients were male. Thirty-seven percent of the patients had upper or middle localized tumor whereas 59 % had epidermoid carcinoma. More than half of the patients (61 %) had undergone operation where 57 % received adjuvant treatment including chemotherapy or chemotherapy plus radiotherapy. Median overall survival was 11.3 ± 1.8 months (95% confidence interval (CI): 7.7–14.9 months). SNCG positivity was significantly associated with the histological type of EC and inoperability (for SNCG positive vs. negative group; epidermoid 80 vs. 53 %; p = 0.05 and inoperable 59 vs.32 %; p = 0.04, respectively). Lymph node metastasis, inoperability and receiving no adjuvant treatment had significantly adverse effect on survival in the univariate analysis (p = 0.01, p < 0.001, and p = 0.001, respectively). SNCG positivity had significantly adverse effect on survival in both univariate and multivariate analysis (p = 0.02 and p = 0.01, respectively). Our results are the first to suggest that SNCG is a new independent predictor for poor prognosis in EC patients in the literature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Surguchov A. Synucleins: are they two-edged swords? J Neurosci Res. 2013;91(2):161–6.

    Article  CAS  Google Scholar 

  2. Ahmad M, Attoub S, Singh MN, Martin FL, El-Agnaf OM. Gamma-synuclein and the progression of cancer. FASEB J. 2007;21(13):3419–30.

    Article  CAS  Google Scholar 

  3. Ninkina N, Papachroni K, Robertson DC, Schmidt O, Delaney L, O’Neill F, et al. Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene. Mol Cell Biol. 2003;23(22):8233–45.

    Article  CAS  Google Scholar 

  4. George JM. The synucleins. Genome Biol. 2002;3(1):REVIEWS3002.

    PubMed  Google Scholar 

  5. Myerowitz R, Mizukami H, Richardson KL, Finn LS, Tifft CJ, Proia RL. Global gene expression in a type 2 Gaucher disease brain. Mol Genet Metab. 2004;83(4):288–96.

    Article  CAS  Google Scholar 

  6. Surgucheva I, McMahan B, Ahmed F, Tomarev S, Wax MB, Surguchov A. Synucleins in glaucoma: implication of gamma-synuclein in glaucomatous alterations in the optic nerve. J Neurosci Res. 2002;68(1):97–106.

    Article  CAS  Google Scholar 

  7. Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G, et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res. 1997;57(4):759–64.

    CAS  PubMed  Google Scholar 

  8. Zhou CQ, Liu S, Xue LY, Wang YH, Zhu HX, Lu N, et al. Down-regulation of gamma-synuclein in human esophageal squamous cell carcinoma. World J Gastroenterol. 2003;9(9):1900–3.

    Article  CAS  Google Scholar 

  9. Luo JH, Zhou J, Gao Y. Correlation between periostin and SNCG and esophageal cancer invasion, infiltration and apoptosis. Asian Pac J Trop Med. 2013;6(7):516–9.

    Article  CAS  Google Scholar 

  10. Liu H, Liu W, Wu Y, Zhou Y, Xue R, Luo C, et al. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res. 2005;65(17):7635–43.

    Article  CAS  Google Scholar 

  11. Lavedan C, Leroy E, Dehejia A, Buchholtz S, Dutra A, Nussbaum RL, et al. Identification, localization and characterization of the human gamma-synuclein gene. Hum Genet. 1998;103(1):106–12.

    Article  CAS  Google Scholar 

  12. Ninkina NN, Alimova-Kost MV, Paterson JW, Delaney L, Cohen BB, Imreh S, et al. Organization, expression and polymorphism of the human persyn gene. Hum Mol Genet. 1998;7(9):1417–24.

    Article  CAS  Google Scholar 

  13. Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 1998;21(6):249–54.

    Article  CAS  Google Scholar 

  14. Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer. 2000;88(9):2154–63.

    Article  CAS  Google Scholar 

  15. Wu K, Weng Z, Tao Q, Lin G, Wu X, Qian H, et al. Stage-specific expression of breast cancer-specific gene gamma-synuclein. Cancer Epidemiol Biomarkers Prev. 2003;12(9):920–5.

    CAS  PubMed  Google Scholar 

  16. Jia T, Liu YE, Liu J, Shi YE. Stimulation of breast cancer invasion and metastasis by synuclein gamma. Cancer Res. 1999;59(3):742–7.

    CAS  PubMed  Google Scholar 

  17. Yanagawa N, Tamura G, Honda T, Endoh M, Nishizuka S, Motoyama T. Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res. 2004;10(7):2447–51.

    Article  CAS  Google Scholar 

  18. Li Z, Sclabas GM, Peng B, Hess KR, Abbruzzese JL, Evans DB, et al. Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer. 2004;101(1):58–65.

    Article  CAS  Google Scholar 

  19. Zhao W, Liu H, Liu W, Wu Y, Chen W, Jiang B, et al. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. Int J Oncol. 2006;28(5):1081–8.

    CAS  PubMed  Google Scholar 

  20. Hu H, Sun L, Guo C, Liu Q, Zhou Z, Peng L, et al. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res. 2009;15(17):5485–93.

    Article  CAS  Google Scholar 

  21. Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, et al. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci. 2004;95(12):955–61.

    Article  CAS  Google Scholar 

  22. Zou J, Fan YJ, Meng YQ, Xu H, Fan J. An exploratory analysis of γ-synuclein expression in endometrioid endometrial cancer. BMJ Open. 2012;2(2):e000611.

    Article  Google Scholar 

  23. Fung KM, Rorke LB, Giasson B, Lee VM, Trojanowski JQ. Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas. Acta Neuropathol. 2003;106(2):167–75.

    Article  CAS  Google Scholar 

  24. Guo J, Shou C, Meng L, Jiang B, Dong B, Yao L, et al. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Int J Cancer. 2007;121(6):1296–305.

    Article  CAS  Google Scholar 

  25. Wu K, Quan Z, Weng Z, Li F, Zhang Y, Yao X, et al. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis. Breast Cancer Res Treat. 2007;101(3):259–67.

    Article  CAS  Google Scholar 

  26. Mhawech-Fauceglia P, Wang D, Syriac S, Godoy H, Dupont N, Liu S, et al. Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma. Gynecol Oncol. 2012;124(1):148–52.

    Article  CAS  Google Scholar 

  27. Morgan J, Hoekstra AV, Chapman-Davis E, Hardt JL, Kim JJ, Buttin BM. Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. Gynecol Oncol. 2009;114(2):293–8.

    Article  CAS  Google Scholar 

  28. Liu C, Dong B, Lu A, Qu L, Xing X, Meng L, et al. Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen. BMC Cancer. 2010;10:359.

    Article  Google Scholar 

  29. Wu K, Huang S, Zhu M, Lu Y, Chen J, Wang Y, et al. Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer. Med Oncol. 2013;30(3):612.

    Article  Google Scholar 

  30. Liu C, Ma H, Qu L, Wu J, Meng L, Shou C. Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas. Hepatogastroenterology. 2012;59(119):2222–7.

    PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Source of funding

No funding source.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Oncology Institute, Istanbul University, 34390, Istanbul, Turkey

    Didem Tastekin & Faruk Aykan

  2. Department of General Surgery, Necmettin Erbakan University, Konya, Turkey

    Suleyman Kargin

  3. Department of General Surgery, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

    Mehmet Karabulut

  4. Department of Pathology, Necmettin Erbakan University, Konya, Turkey

    Naile Yaldız

  5. Department of Radiation Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey

    Makbule Tambas & Necla Gurdal

  6. Department of Medical Oncology, Van Training and Research Hospital, Van, Turkey

    Ali Murat Tatli

  7. Department of Medical Oncology, Erzurum Training and Research Hospital, Erzurum, Turkey

    Deniz Arslan

  8. Department of General Surgery, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    Ali Fuat Kaan Gok

Authors
  1. Didem Tastekin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suleyman Kargin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mehmet Karabulut
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naile Yaldız
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Makbule Tambas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Necla Gurdal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ali Murat Tatli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Deniz Arslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ali Fuat Kaan Gok
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Faruk Aykan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Didem Tastekin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tastekin, D., Kargin, S., Karabulut, M. et al. Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients. Tumor Biol. 35, 11871–11877 (2014). https://doi.org/10.1007/s13277-014-2429-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2429-4

Keywords

Search

Navigation